Oligomeric HIV-1 envelope glycoproteins

US6039957A · kind A · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Patricia Earl · Bethesda, US
• Christopher C. Broder · Silver Spring, US
• Robert Doms · Berwyn, US
• Bernard Moss · Bethesda, US

Key dates

• Filing date: Mar 3, 1997
• Grant date: Mar 21, 2000
• Expiry date: Mar 3, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to methods for producing recombinant HIV-1 envelope (env) oligomers for use as immunogens. When gp140 oligomeric glycoproteins were purified by sucrose velocity gradient sedimentation, and then used to immunize mice, the resulting humoral immune response was skewed toward the production of antibodies that recognize conformation-dependent epitopes on the HIV-1 env protein. Assays for HIV-1 infections are described, as well as immonogens for vaccinating against HIV-1 infection.